FDA Approves Ipilimumab for Pediatric Melanoma
July 24, 2017 - The FDA has approved ipilimumab for the treatment of patients aged ≥12 years with unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor. The expanded indication for ipilimumab is based ...Leggi tutto
